Abstract
Detrimental impact of chemotherapy dose reduction or discontinuation in early stage triple-negative breast cancer treated with pembrolizumab and neoadjuvant chemotherapy: A multi-center experience
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have